Fairfield, Bush & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Fairfield, Bush & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201K	Buy	+1,270	New	+$172K	0.1%	124

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Fairfield, Bush & Co's XBI Position: Q2 2026 in Review

Fairfield, Bush & Co opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 1,270 shares worth $201K. The stake represents 0.1% of the portfolio and ranks #124 among its holdings.

932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Fairfield, Bush & Co held 1,270 shares of State Street SPDR S&P Biotech ETF worth $201K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Fairfield, Bush & Co position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.1% of Fairfield, Bush & Co's portfolio in Q2 2026, its #124 holding.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Fairfield, Bush & Co's 13F filing for Q2 2026, filed 13 Aug 2026.